Dosage
Biogen Announces Positive Results from Higher Dose Spinraza Study in Spinal Muscular Atrophy Patients
Biogen, Spinraza, spinal muscular atrophy, SMA, higher dose, clinical trial, DEVOTE study
Minimal Weight Reduction Observed with Low Doses of New Zealand’s GLP-1/GLP-2 Agonist
New Zealand, GLP-1/GLP-2 agonist, weight reduction, lowest doses, minimal effect.